Ionis Pharmaceuticals, Inc. announced to host its 2025 Innovation Day in New York City. The company’s leaders will present recent and upcoming independent product launches, its growing pipeline of wholly owned medicines, innovative technologies, and a roadmap toward sustained positive cash flow.
A leading physician will also address the current treatment landscape and the significant unmet needs in severe hypertriglyceridemia (sHTG) ahead of the potential launch of olezarsen.
Ionis owned program will highlight the following key areas:
- Building a leading cardiometabolic disease portfolio
- DAWNZERA: Transforming the HAE treatment paradigm
- Advancing their leading neurology portfolio
- Creating substantial value through accelerating growth
For past decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need.
Executive Statement
According to Brett P. Monia, Ph.D., chief executive officer of Ionis, in less than nine months, they achieved two independent launches, marking significant progress toward their goal of transforming human health by bringing RNA-targeted medicines to people with serious diseases. Their accelerating growth is driven by an industry-leading pharma pipeline, with two more independent launches planned for 2026, four partner launches by the end of 2027 and continued advancement of their leading technology platform to deliver next-generation medicines. Innovation Day highlights how Ionis is creating substantial and enduring value for patients and shareholders through groundbreaking science and the ability to deliver medicines now and in the future.
